BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of ...
PGN Architects, a D.C.-based architecture firm behind projects like the Strand Residences in Deanwood and the MDL Flats affordable apartment complex in Buzzard Point, is being acquired by Princeton, ...
- Safety, transcript splicing correction and clinical outcome measures data at 5 mg/kg PGN-EDODM1 dose level in patients from FREEDOM-DM1 clinical trial expected in 2024 - - Clearance of Clinical ...
- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with mutations amenable to skipping exon 51 - - Initial data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results